中国临床药理学杂志2024,Vol.40Issue(6):815-819,5.DOI:10.13699/j.cnki.1001-6821.2024.06.007
巴戟天寡糖胶囊用于轻、中度抑郁症患者巩固期治疗的临床研究
Clinical trial of Morinda officinalis oligosaccharides in the continuation treatment of adults with mild and moderate depression
摘要
Abstract
Objective To observe the efficacy and safety of Morinda officinalis oligosaccharides in the continuation treatment of mild and moderate depression.Methods An open,single-arm,multi-center design was adopted in our study.Adult patients with mild and moderate depression who had received acute treatment of Morinda officinalis oligosaccharides were enrolled and continue to receive Morinda officinalis oligosaccharides capsules for 24 weeks,the dose remained unchanged during continuation treatment.The remission rate,recurrence rate,recurrence time,and the change from baseline to endpoint of Hamilton Depression Scale(HAMD),Hamilton Anxiety Scale(HAMA),Clinical Global Impression-Severity(CGI-S)and Arizona Sexual Experience Scale(ASEX)were evaluated.The incidence of treatment-related adverse events was reported.Results The scores of HAMD-17 at baseline and after treatment were 6.60±1.87 and 5.85±4.18,scores of HAMA were 6.36±3.02 and 4.93±3.09,scores of CGI-S were 1.49±0.56 and 1.29±0.81,scores of ASEX were 15.92±4.72 and 15.57±5.26,with significant difference(P<0.05).After continuation treatment,the remission rate was 54.59%(202 cases/370 cases),and the recurrence rate was 6.49%(24 cases/370 cases),the recurrence time was(64.67±42.47)days.The incidence of treatment-related adverse events was 15.35%(64 cases/417 cases).Conclusion Morinda officinalis oligosaccharides capsules can be effectively used for the continuation treatment of mild and moderate depression,and are well tolerated and safe.关键词
巴戟天寡糖胶囊/抑郁症/疗效/安全性Key words
Morinda officinalis oligosaccharides/depression/efficacy/safety分类
医药卫生引用本文复制引用
周书喆,海英,贾智捷,王占敏,魏琰,朱建国,宋学勤,刘志东,况利,王洪明,田峰,韩祖成,李玉欣,张玲,林海,吴斌,王超英,刘畅,孙佳凡,闫少校,刘君,谢守付,王秀珍,房茂胜,宓为峰,张鸿燕,陈燕清,呼亚玲,余雪芹,王斌红,樊国珍,桑红..巴戟天寡糖胶囊用于轻、中度抑郁症患者巩固期治疗的临床研究[J].中国临床药理学杂志,2024,40(6):815-819,5.基金项目
国家"重大新药创制"科技重大专项课题基金资助项目(2014ZX09301307014) (2014ZX09301307014)